Manila Bulletin
AstraZeneca vaccines need to get FDA approval, says Duque; supply agreement could still be discarded
The deal for AstraZeneca's COVID-19 vaccine in the Philippines can be canceled if the vaccine does not receive approval from the Food and Drug Administration (FDA), according to Health Secretary Francisco Duque III.
Duque stated that the tripartite agreement necessitates the vaccine to pass evaluations by vaccine experts and the FDA.
He indicated that the agreement could be voided if any issues are found regarding the vaccine's safety, quality, and efficacy.
The Department of Health previously confirmed that the vaccine would not be administered to Filipinos without regulatory clearance.
AstraZeneca is also required to conduct Phase 3 clinical trials in the Philippines, not just abroad.
The supply deal, facilitated by the private sector, was an advanced commitment to secure 2.6 million doses of the vaccine for the Philippines.
AstraZeneca's vaccine has reportedly shown 70% effectiveness with a half dose and 90% effectiveness with a full second dose.
The vaccine is currently under evaluation by the Philippine Vaccine Experts Panel and the Ethics Review Board.
Topics in this story
Explore more stories about these topics.
🤖
This story was generated by AI to help you understand the key points. For more detailed coverage, please see the news articles from trusted media outlets below.
News Sources
See how different news organizations are covering this story. Below are the original articles from various Philippine news sources that contributed to this summary.
